Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for High-Grade Cervical Intraepithelial Lesions
NCT03233412Phase 2Completed
- Sponsor
- Hospital de Amor
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Hospital de Amor. Primary endpoint: Efficacy of immunomodulatory treatment compared to LEEP at 30 months. Started Jan 2018; status: completed.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03233412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233412.